Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Investor Presentation (August 2026)
29 slides from Vivani Medical's investor presentation, Aug 17, 2026
Slide 1: Vivani Medical, Inc.
Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. www.vivani.com August 17, 2026
Slide 2: Disclaimers
Disclaimers The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "safe ha
Slide 3: The obesity market is evolving
The obesity market is evolving What will it take to be successful in the future? In addition to the currently FDA-approved products on the market, there are over 50 in clinical development. All of these are injectables or orals. Vivani’s implant uniquely combines infrequent (e.g., once- or twice-yea
Slide 4: Vivani's differentiated product candidates are designed to address unmet needs and expand the market
Vivani’s differentiated product candidates are designed to address unmet needs and expand the market Market Challenges The NanoPortal Promise Suboptimal outcomes Convenient, guaranteed adherence Poor medication adherence (<50%) leads to Designed to maintains therapeutic effect and loss of efficacy a
Slide 5: Vivani Medical, Inc.
Vivani Medical, Inc. A clinical stage innovator uniquely positioned to address the future Nasdaq: VANI challenges and opportunities of an evolving obesity market Cash runway expected to Our focus: Enhance patient outcomes and GLP-1 market uptake in chronic fund current operating plan, diseases via u
Slide 6: Company pipeline utilizing NanoPortal platform
Company pipeline utilizing NanoPortal platform If approved, Vivani products would provide a differentiated ultra long-acting option for patients Indication Feasibility Preclinical Clinical Obesity/Weight NPM-139 Management semaglutide Obesity/Weight Next-generation Management incretins* Vivani Obesi
Slide 7: Good things come in small packages
Good things come in small packages 01 GLP-1 implant & applicator 02 NanoPortal device elements 03 NanoPortal technology ✓ Designed to assure adherence ✓ Nanotube pore size is precisely tunable to achieve near-constant release ✓ Long-term delivery profiles ✓ Stable and tunable release profile ✓ Simpl
Slide 8: NanoPortal delivers smooth, near-constant drug release
NanoPortal delivers smooth, near-constant drug release Day 1 timepoint includes cumulative release over the first day including a separately measured 1st hour of release, which was ~7 µg for the high-dose and ~4 µg for the low- dose. Values are mean ± SD. *Release-rates include exenatide and related
Slide 9: In vitro and in vivo performance of 12-week GLP-1 implant configuration
In vitro and in vivo performance of 12-week GLP-1 implant configuration In vitro release-rate of exenatide implant (n=17). Individual values are In vivo pharmacokinetics of 12-week exenatide implant and sham implant included for each timepoint. Each week consists of two 24-hour intervals and a in hi
Slide 10: Preclinical GLP-1 NanoPortal implant is associated with durable body weight effects
Preclinical GLP-1 NanoPortal implant is associated with durable body weight effects A B Weight difference from control in healthy Sprague-Dawley Rats. % weight change from baseline for a single administration of exenatide implant in a study associated with NPM-119 (~320 nmol/kg/day) corrected to con
Slide 11: GLP-1 NanoPortal implant reduced liver fat by 82% in preclinical study
GLP-1 NanoPortal 35.0 implant reduced liver 30.0 fat by 82% in preclinical study 25.0 Liver fat (% Area) 20.0 15.0 10.0 5.0 Liver fat reduction in high fat diet-induced obese mice. Liver fat % area for exenatide 0.0 Sham Implant Exenatide Implant implant vs sham implant 12 weeks after a single (n=7)
Slide 12: First-in-human GLP-1 NanoPortal clinical trial: LIBERATE-1
First-in-human GLP-1 NanoPortal clinical trial: LIBERATE-1 Primary Objectives Key Inclusion/Exclusion Criteria Safety/tolerability assessment and full pharmacokinetic 18-55 years old; overweight or obese (BMI 27-40) characterization. Changes in weight also assessed. Otherwise healthy (no T2D, normal
Slide 13: LIBERATE-1 topline results summary
LIBERATE-1 topline results summary Implant well-tolerated No serious adverse events in the study No clinically meaningful initial burst Encouraging release profile No evidence of dose dumping Potential for durable long-term delivery confirmed Primary study objectives were met: Further NanoPortal cli
Slide 14: Vivani Lead Program: NPM-139
Vivani Lead Program: NPM-139 SLIM : Semaglutide ultra Long-acting IMplant in obesity
Slide 15: Priority clinical development program: NPM-139
Priority clinical development program: NPM-139 Development of once- or twice-yearly semaglutide implant for chronic weight management in obese or overweight patients FDA-approved GLP-1 Based on real-world The initial program products generated adherence and activities are being $132B in global sales
Slide 16: Persistence and adherence are critical to securing desired long-term health outcomes
Persistence and Large Retrospective Cohort Study* (N=1,911) adherence are critical 6 months 12 months to securing desired long-term health 100% outcomes Percent Remaining on Therapy 75% Persistence data comparing obesity therapies suggest room for improvement across the board, 50% including for sema
Slide 17: Semaglutide discontinuation leads to rapid hunger-induced weight rebound
Semaglutide discontinuation leads to rapid hunger- induced weight rebound Sudden GLP-1 withdrawal produces immediate rebound hunger, leading to rapid weight regain mediated by greater food consumption STEP 1 Extension: Semaglutide Withdrawal From Novo Nordisk Wegovy® Clinical Program 17
Slide 18: NPM-139 provides steady preclinical pharmacokinetics
NPM-139 provides steady preclinical 3 pharmacokinetics In vivo pharmacokinetics of NPM-139 configurations in Sprague-Dawley rats. Values are mean ± SE. *n=5 through day 28; two implants removed at Day 28 for characterization, n=3 thereafter. 18
Slide 19: Prototype semaglutide NanoPortal implant demonstrates sustained weight loss and delivery for a full year
Prototype A B semaglutide NanoPortal implant demonstrates sustained weight explanted devices loss and delivery for a full year Prototype NPM-139, prior to PK optimization. In Vivo Normalized semaglutide plasma concentrations remain measurable Pharmacokinetics and Weight loss vs. control in Sprague-
Slide 20: Patient and prescriber market research signals strong adoption potential
Patient and prescriber market research signals strong adoption potential for an ultra-long-acting GLP-1 implant Currently on a GLP-1 therapy (n=324) Patient market research 56% of GLP-1 patients responded “likely” 11% 33% 42% 14% or “definitely” to get a GLP-1 implant if FDA approved, prescriber rec
Slide 21: Contraception analog provides further support for the commercial potential for a miniature GLP-1 implant
Contraception analog provides further support for the commercial potential for a miniature GLP-1 implant THE CONTRACEPTION MARKET: AN ANALOG FOR GLP-1s Both require chronic dosing, with therapeutic options spanning oral pills and long-acting implants. Among U.S. women using a drug or device for cont
Slide 22: NPM-139 clinical and regulatory development: Near-term plan builds on recent wins
NPM-139 clinical and regulatory development: Near-term plan builds on recent wins Milestone Status Reported preclinical proof of concept (~20% weight loss) with NPM-139 August 2025 (semaglutide implant) Received regulatory approval to initiate SLIM-1 clinical trial June 2026 Announced Novo Nordisk a
Slide 23: NPM-139 Phase 1 study design: SLIM-1
NPM-139 Phase 1 study design: SLIM-1 Primary Objectives Key Inclusion/Exclusion Criteria Safety/tolerability assessment and pharmacokinetic 18-55 years old; overweight or obese (BMI 27-40) characterization Otherwise healthy (no T2D) Screen and Treatment (4 Weeks) EOT Randomize (~21 days) NPM-139 (se
Slide 24: Proposed NPM-139 Phase 2 study design: SLIM-2
Proposed NPM-139 Phase 2 study design: SLIM-2 Randomize Run-In (20 weeks) Randomized Treatment Period (16 or 24 weeks) Semaglutide Implant Dose 3 Semaglutide Implant Dose 2 2.4 mg Semaglutide Implant Dose 1 1.7 mg 1.0 mg Placebo (sham implant) 0.5 mg Semaglutide 0.25 mg Wegovy® (semaglutide injectio
Slide 25: NanoPortal retatrutide implant provides steady preclinical pharmacokinetics
NanoPortal retatrutide implant provides steady 3 preclinical pharmacokinetics in ongoing study In vivo pharmacokinetics of prototype NanoPortal retatrutide implant in Sprague-Dawley rats in an ongoing study. Values are mean ± SE. 25
Slide 26: Vivani headquarters and GMP manufacturing facility
Vivani headquarters and GMP manufacturing facility 26
Slide 27: The Vivani executive leadership team
The Vivani executive leadership team Donald Dwyer, MBA Lisa Porter, MD Chief Business Officer Chief Medical Officer ✓ Former Executive Director at AstraZeneca with ✓ Former Chief Medical Officer for Eiger leadership roles in regulatory affairs, drug BioPharmaceuticals and Dance BioPharm Adam Mendels
Slide 28: Guaranteed adherence. Improved outcomes.
Guaranteed adherence. Improved outcomes. Only GLP-1 implant in development for obesity and chronic weight management Convenient once- or twice-yearly dosing expected to address primary GLP-1 market challenges Unique modality designed to reach underserved & unaddressed populations key to market expan
Slide 29: Thank You
Thank You Company Contact: Donald Dwyer, Chief Business Officer info@vivani.com Investor Relations Contact: Jami Taylor, Investor Relations Advisor investors@vivani.com www.vivani.com